For example, in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors, ctDNA analysis at the time of resistance can identify mechanisms of resistance such as secondary EGFR mutations and MET amplification182,184. This evidence concerns the gene MET and non-small cell lung carcinoma.